SIGA - SIGA Technologies, Inc.

SIGA Technologies, Inc.

27 East 62nd Street
New York, NY 10065
United States
212-672-9100
http://www.siga.com

Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 37

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Phillip Louis Gomez III	CEO & Director	1.66M	N/A	1967
Mr. Daniel J. Luckshire	Exec. VP, CFO & Sec.	1.04M	N/A	1971
Dr. Dennis E. Hruby	VP & Chief Scientific Officer	1.16M	327.38k	1952
Ms. Robin E. Abrams	Gen. Counsel & Chief Admin. Officer	1.01M	N/A	1964
Dr. Eric A. Rose	Consultant	732.17k	437.1k	1951

Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security markets in the United States. Its lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was founded in 1995 and is headquartered in New York, New York.

Corporate Governance

SIGA Technologies, Inc.’s ISS Governance QualityScore as of February 1, 2019 is 9. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.